Tianxin Pharma’s Generic Drug Passes Key Evaluation
Company Announcements

Tianxin Pharma’s Generic Drug Passes Key Evaluation

Guangzhou Baiyunshan Pharmaceutical Holdings Company (HK:0874) has released an update.

Guangzhou Baiyunshan Pharmaceutical Holdings Company’s subsidiary, Tianxin Pharmaceutical, has received approval from the National Medical Products Administration for its generic drug, Cefoperazone Sodium for Injection (0.5g, 1.0g), which has passed the quality and therapeutic consistency evaluation. This achievement assures the drug’s quality and effectiveness, aligning with industry standards. The company’s board and directors have confirmed the authenticity and completeness of this announcement, assuming legal responsibility for its truthfulness.

For further insights into HK:0874 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks HongKong Auto-Generated NewsdeskGuangzhou Baiyunshan Reports Mixed Financial Results
TipRanks HongKong Auto-Generated NewsdeskGuangzhou Baiyunshan’s Strategic Asset Disposal Unveiled
TipRanks HongKong Auto-Generated NewsdeskGuangzhou Baiyunshan Schedules Financial Review Meeting
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App